Introduction {#s1}
============

Canine hyperadrenocorticism is an endocrine disease routinely encountered within primary care veterinary practice with an estimated prevalence of 0.28 per cent.[@R1] The disease is most commonly due to a functional pituitary tumour, although in approximately 15 per cent of cases an adrenal tumour causes the excessive circulatory glucocorticoids which ultimately produce the classical clinical signs in affected dogs.[@R2] Depending on the duration of the disease, these cases show various combinations of polydipsia, polyuria, polyphagia, muscle atrophy, hepatomegaly, lethargy and dermatological changes.[@R1] The disease is generally associated with older age, with the average age at diagnosis within primary care practice of nine years.[@R1] Alongside their older age, the disease often occurs in dogs as one of multiple morbidities including diabetes mellitus (in \~10 per cent of hyperadrenocorticism cases), calcium oxalate urolithiasis, hypothyroidism, pancreatitis and hypertension; however, the causal relationships between these diseases are unproven.[@R5] The typical treatment for hyperadrenocorticism in UK dogs is trilostane (Vetoryl Capsules, Dechra Veterinary Products); however, other medical and surgical options are available.

A good understanding of the survival characteristics of dogs with hyperadrenocorticism attending primary care practices is useful for practising veterinary surgeons when informing dog owners. These prognostic indicators play an important role in presenting options for diagnosis as well as treatment, especially given the ongoing expense of treatment and the fact that the disease typically occurs in an older animal where euthanasia may be more frequently considered than disease occurring in younger dogs.[@R11] Most of the existing survival data have examined dogs undergoing treatment for the disease in a referral setting or outside of the UK with studies separating pituitary-dependent disease (PDH) and adrenal-dependent disease (ADH). Median survival times in dogs with PDH treated with trilostane in referral settings have been shown to range from 662 to 900 days.[@R5] This is compared to the median survival times of trilostane-treated dogs with ADH which are reported between 353 and 475 days.[@R4] A retrospective study in Japan examined the survival times of 43 dogs with hyperadrenocorticism under primary care and found a statistical difference between dogs treated with trilostane and those not receiving any treatment.[@R6] Survival times of surgically managed hyperadrenocorticism report 72 per cent--79 per cent survival after 4 years in dogs having undergone hypophysectomy for PDH[@R15] and 533--953 days median survival of ADH cases undergoing adrenalectomy.[@R17] Older age, increased post-adrenocorticotropic hormone (ACTH) cortisol concentrations and increased bodyweight have all been associated with a poorer prognosis for dogs with hyperadrenocorticism.[@R5]

The aim of this study was to examine veterinary clinical records to assess the survival characteristics of dogs diagnosed with hyperadrenocorticism under primary care in England. The hypotheses for this study were that age, weight and post-ACTH cortisol concentrations are associated with survival. It was further hypothesised that trilostane treatment favoured survival compared with those that did not receive treatment.

Materials and methods {#s2}
=====================

A retrospective cohort design was used to examine the risk factors for all-cause mortality in the study population. The study used routinely recorded primary care clinical data collected within the Veterinary Companion Animal Surveillance System project, VetCompass[@R19] and included all dogs under veterinary care at collaborating practices in England between January 1, 2009 and December 31, 2013. The end of follow-up for the study was Aprril 4, 2018. Available clinical data for the study included the attending veterinary surgeons' clinical notes, laboratory results and prescribed treatments recorded within the anonymised electronic patient records (EPRs). The case definition for incident cases of hyperadrenocorticism required the dog to have one of the following: i) a definitive diagnosis of hyperadrenocorticism recorded in the clinical notes; ii) at least one recorded prescription of trilostane, with at least one commonly used screening test for hyperadrenocorticism recorded (ACTH stimulation test, low-dose dexamethasone suppression test (LDDST) or urine cortisol-creatinine ratio (UCCR)). Cases reported as iatrogenic within the EPR were excluded from analysis. The search protocol used to find hyperadrenocorticism cases involved searching the EPR of all study dogs using key search terms (eg, cushin\*, hyperadreno\*, hac) to identify candidate cases with a higher probability of hyperadrenocorticism. The full clinical records of a random sample of 52 per cent of these candidate cases were manually checked to evaluate against the hyperadrenocorticism case definition and the study inclusion criteria.

Available demographic data for all study dogs included age, sex, neuter status, insurance status, breed, maximum recorded bodyweight and clinic ID. Continuous variables were assessed for linearity with the outcome; where the associations were non-linear, the continuous variables were categorised for analysis. Age at diagnosis (years) was calculated by using their date of birth and date the attending veterinary surgeon diagnosed hyperadrenocorticism. This was categorised into three groups, based around the median age of the study population: less than 10, 10 to less than 13 and greater than or equal to 13 (years). Insurance status was as recorded in the EPRs as 'insured', 'uninsured' or 'unknown' in those with missing information. Individual breeds were included in the analysis if there were greater than or equal to 12 hyperadrenocorticism case dogs of that breed. All other breeds were grouped as 'purebred other'. Maximum recorded bodyweight was split into two groups based around the median weight of dogs within the study population: those less than 15 kg and those greater than or equal to 15 kg. The variable of 'weight compared with breed average' was calculated by comparing the dog's maximum recorded weight with the corresponding breed average.[@R1]

Additional risk factors and data were extracted manually: date of first diagnosis, date of censorship or death, treatment data reported, recorded comorbidities and diagnostic ACTH blood results. The date of first diagnosis and inclusion into the study was defined as either the first date for a recorded final diagnosis or the first date that trilostane was prescribed for cases without a formally recorded diagnostic term in the clinical notes. The end date was recorded as the date of death or date of the last clinical record during the study period in those that were censored (those still alive at the end of the study period or lost to follow-up). Trilostane dose (mg/kg/day) was recorded from the clinical notes or manually calculated using the prescribed amount (mg) given to the dogs and the nearest recorded weight (kg) to the date of treatment. Trilostane dose was calculated each time a change to the dose was made by the attending veterinarian permitting calculation of the dogs' mean lifetime trilostane dose weighted by the length of time spent on each dose ((dose 1×x days+dose 2×y days+....)/total number of days). A binary variable grouped those with a mean lifetime trilostane dose less than or equal to 3 mg/kg/day and those greater than 3 mg/kg/day. This cut off was based on the recommended starting doses for trilostane in dogs during the study period.[@R20] Further information on trilostane was extracted including frequency of dose administration and whether changes were made to the initial dose (increased, decreased, stopped or no change made). A comorbidity was recorded if the dog had another chronic disease, as diagnosed in the EPR (either before or subsequently hyperadrenocorticism) or there was evidence of treatment or management of a chronic disease concurrently with hyperadrenocorticism.[@R21] This included chronic heart disease, diabetes mellitus, hypertension, hypothyroidism, chronic kidney disease, chronic hepatitis, chronic skin disease (atopy or chronic pyoderma), urolithiasis, malignant neoplastic disease and osteoarthritis. Concurrent diabetes mellitus and hypertension were analysed as separate risk factors.[@R10] Hypertension was defined as those with a conscious systolic arterial blood pressure measurement recorded at greater than 150 mmHg or a diagnosis recorded in the free text.[@R23] Dogs with neurological signs were defined as those with one or more of the following: seizures with no attributed alternative diagnosis, behaviour change, signs of cognitive dysfunction or apparent blindness.[@R24]

Data were cleaned in Microsoft Excel (Microsoft, Redmond, Washington, USA) before being uploaded into Stata V.15 (StataCorp, College Station, Texas, USA) for statistical analysis. Categorical data were presented showing the count and corresponding percentage. Quantitative data were assessed graphically for normality with normally distributed data summarised using the mean (sd) and non-normally distributed data using the median (IQR and range). Chi-squared analysis compared the association between two categorical risk factors. A Kaplan-Meier plot described the all-cause mortality trend of the case dogs and survival differences were explored using the log-rank test. Median survival time was defined as the point at which the cumulative percentage of dogs surviving from the date of hyperadrenocorticism diagnosis reached 50 per cent.[@R26] Univariable and multivariable Cox proportional hazard modelling were used to assess associations between the recorded risk factors and hazard of death (all-cause mortality). Risk factors in the univariable analysis with a likelihood ratio test (LRT) of P\<0.2 for the outcome of dying were carried forward for multivariable modelling. A forwards stepwise manual approach was used to build the multivariable model with risk factors kept in the final model after assessing for effects of confounding and if they were associated with the outcome of dying (LRT P\<0.05). The proportional hazards assumption that the HRs are constant over time was assessed by visual inspection of log-minus-log survival plots and by statistical assessment of Schoenfeld residuals.[@R27] The clinic ID was assessed as a frailty term to account for the correlated nature of the data across different veterinary practices with the LRT of theta used to assess if within-patient correlation affected the model. Age was assessed for linearity using the LRT for extralinear effect and goodness of fit of the final model was evaluated using visual inspection of Cox-Snell residuals.[@R26] Confounding factors were assessed by substantial variation in HRs with inclusion of an additional risk factor. Plausible pairwise interactions were examined with the LRT of homogeneity. Dogs with missing data for the risk factors of interest were excluded from the multivariable Cox proportional hazards models. Missing data were also excluded from the univariable analysis if the missing category was the sole reason for a significant risk factor variable (P\<0.2).

Sample size calculations using Stata V.15 estimated that for a Cox proportional hazards analysis 208 dogs would be required to observe an HR of 2 at 5 per cent significance, 80 per cent power, with an expected proportion of deaths at 80 per cent and 15 per cent lost to follow-up.

Results {#s3}
=======

Descriptive statistics {#s3-1}
----------------------

The study included 193,814 dogs attending 110 primary care veterinary practices in England between January 1, 2009 and December 31, 2013. Of the 2502 dogs identified as candidate hyperadrenocorticism cases from the search terms, 1178 (52.0 per cent) were manually reviewed in detail against the case definition. From these candidate cases 219 dogs were included in the analysis. There were 179 (81.7 per cent) cases that died within the study period with 136 (76.0 per cent) of these recorded to be via euthanasia. The remaining 34 (15.5 per cent) dogs were censored and 6 were still alive at the end of the study observation. Median follow-up time for cases was 424 days (IQR 119--779 days, range 1--2192 days).

The maximum recorded bodyweight (kg) of the cases was heavily right skewed with a median of 12.75 kg (IQR 9.20--21.00, range 2.48--65.90). The age at diagnosis (years) was normally distributed with a mean age of 10.99 years (sd 2.49) and a range of 4.46--18.00 years. The cases included 104 females and 115 males of which 86 (82.7 per cent) and 83 (72.2 per cent) were recorded as neutered, respectively. The most represented breed-types were crossbreeds (n=47, 21.5 per cent), Jack Russell terriers (21, 9.6 per cent), Yorkshire terriers (16, 7.3 per cent), Bichon Frise (13, 5.9 per cent), Staffordshire bull terriers (13, 5.9 per cent) and West Highland white terriers (12, 5.5 per cent). Insurance status was unrecorded in 41 dogs with 126 (57.5 per cent) known to be insured. The proportion insured increased to 70.2 per cent in those weighing greater than or equal to 15 kg (chi-squared test, P=0.01). Overall, 206 (94.1 per cent) of the cases received trilostane at some point within their clinical history, 1 dog (0.5 per cent) had surgical treatment via unilateral adrenalectomy and the remaining 12 dogs never received any treatment. Of the dogs initially treated with trilostane, 32 (15.5 per cent) later had their treatment ceased. The starting dose of trilostane was available for 199 (96.6 per cent) cases and was normally distributed around the manufacturer's recommended starting doses with a mean of 3.30 mg/kg/day (sd 1.28).[@R20] The mean lifetime trilostane dose was skewed to the right with a median dose of 3.09 mg/kg/day (IQR 2.45--4.50). Frequency of dosing was available for 194 (94.2 per cent) cases with 178 (91.8 per cent) receiving once-daily dosing of trilostane for the duration of their treatment. Of the 100 (48.5 per cent) cases with blood test results recorded at each monitoring ACTH stimulation test, 32 dogs never had a post-ACTH cortisol drop below the upper reference range of 250 nmol/l and 21 had results fall below the lower reference range 40 nmol/l at least once.[@R28] There were 28 dogs with suspected iatrogenic hypoadrenocorticism or adverse response to trilostane at some point in their EPR that were managed by either reducing the trilostane dose or stopping treatment. The most commonly used diagnostic screening tests reported to have been used were the ACTH stimulation test (n=206, 94.1 per cent), LDDST (70, 32.0 per cent) and UCCR (58, 26.5 per cent). All dogs had at least an ACTH stimulation test or an LDDST recorded before diagnosis. Hyperadrenocorticism was differentiated in 44 (20.1 per cent) cases: 30 (68.2 per cent) had PDH and 14 (31.8 per cent) had ADH. Differentiation was based on reported interpretation of ultrasonographic imaging of the adrenals and interpretation of an LDDST. At least one comorbidity to hyperadrenocorticism was recorded in 141 cases (68.5 per cent). Of these, 61.0 per cent had one other comorbidity and a maximum of five comorbidities. Forty-five cases (11.5 per cent) were recorded with central neurological signs, 22 (10.1 per cent) dogs concurrently had diabetes mellitus and 6 (2.7 per cent) had concurrent hypothyroidism.

Survival analysis {#s3-2}
-----------------

The overall median survival time following diagnosis with hyperadrenocorticism (n=219) was 510 days (95% CI 412 to 618 days) ([figure 1](#F1){ref-type="fig"}). Median survival time for cases treated with trilostane (n=206) was 521 days (95% CI 416 to 634 days) and did not differ statistically from the 18 cases not treated with trilostane (178 days, 95% CI 3 to 1015 days, P=0.590). Median survival time for cases that had trilostane treatment ceased or were untreated was 484 days (95% CI 373 to 689) compared with 517 days in those continuously kept on treatment (95% CI 376 to 637 days, P=0.688). Of the dogs where disease differentiation was recorded by the attending veterinary surgeon, the median survival time of those with ADH was 596 days (n=14, 95% CI 166 to 941) and did not differ statistically from the 30 dogs diagnosed with PDH (700 days, 95% CI 305 to 1125, P=0.31). The cumulative proportion of all cases surviving to one year was 0.60 (95% CI 0.53 to 0.66) with 0.35 (95% CI 0.28 to 0.41) surviving to two years.

![Kaplan-Meier survival curve of all-cause mortality in dogs diagnosed with hyperadrenocorticism at UK primary care practices. Survival time represents the time from when the disease was initially detected until the time of death due to all-cause mortality.](vetrec-2018-105159f01){#F1}

Univariable Cox proportional hazards analysis identified loose association (P\<0.2) of the following risk factors that were taken forward to the final multivariable model: bodyweight, age, insurance status, neurological signs, changes in trilostane dosage and diagnostic pre-ACTH and post-ACTH cortisol levels ([table 1](#T1){ref-type="table"}). Univariable analysis did not identify associations with any breeds. The origin of the disease and whether or not dogs were treated with trilostane also did not show an association with all-cause mortality in the univariable analysis.

###### 

Univariable Cox proportional hazards regression analysis for risk factor association with death (all-cause mortality) in dogs diagnosed with hyperadrenocorticism at primary care veterinary practices in England (n=219)

  Variable                                Frequency (%)   Median survival time (days)   95% CI        HR         95% CI         Category P value\*   Variable P value†
  --------------------------------------- --------------- ----------------------------- ------------- ---------- -------------- -------------------- -------------------
  Weight (kg)                                                                                                                                        0.002
   \<15                                   135 (61.6)      634                           424 to 726    Baseline   \-             \-                   
   ≥15                                    84 (38.4)       427                           296 to 530    1.61       1.19 to 2.18   0.002                
  Age at diagnosis (years)                                                                                                                           
   \<10                                   74 (33.8)       718                           593 to 896    Baseline   \-             \-                   \<0.001
   10 to \<13                             96 (43.8)       458                           319 to 637    1.48       1.04 to 2.12   0.029                
   ≥13                                    49 (22.4)       239                           144 to 449    2.94       1.93 to 4.48   \<0.001              
  Sex neuter                                                                                                                                         
   Female entire                          18 (8.2)        427                           178 to 1223   1.04       0.56 to 1.92   0.911                0.899
   Female neutered                        86 (39.3)       442                           355 to 637    Baseline   \-             \-                   
   Male entire                            32 (14.6)       535                           159 to 714    1.13       0.73 to 1.76   0.578                
   Male neutered                          83 (37.9)       546                           376 to 718    0.95       0.68 to 1.33   0.780                
  Sex                                                                                                                                                
   Female                                 104 (47.5)      440                           355 to 637    Baseline   \-             \-                   0.970
   Male                                   115 (52.5)      535                           376 to 683    0.99       0.74 to 1.34   0.970                
  Neuter status                                                                                                                                      
   Entire                                 50 (22.8)       535                           220 to 714    Baseline   \-             \-                   
   Neutered                               169 (77.2)      510                           412 to 618    1.13       0.79 to 1.61   0.501                0.506
  Insured                                                                                                                                            
   Yes                                    126 (57.5)      517                           412 to 642    0.74       0.52 to 1.07   0.113                0.059
   No                                     52 (23.7)       332                           219 to 535    Baseline   \-             \-                   
   Unrecorded                             41 (18.8)       717                           442 to 896    0.55       0.34 to 0.91   0.018                
  Breed                                                                                                                                              
   Crossbred                              47 (21.5)       432                           221 to 726    Baseline   \-             \-                   0.286
   Bichon Frise                           13 (5.9)        540                           119 to 1259   0.72       0.36 to 1.45   0.361                
   Jack Russell terrier                   21 (9.6)        807                           484 to 1445   0.57       0.31 to 1.04   0.065                
   Staffordshire bull terrier             13 (5.9)        700                           215 to 941    1.01       0.54 to 1.89   0.977                
   West Highland white terrier            12 (5.5)        396                           72 to 1022    0.93       0.46 to 1.85   0.832                
   Yorkshire terrier                      16 (7.3)        642                           239 to 1015   0.80       0.43 to 1.50   0.487                
   Other purebreds                        97 (44.3)       440                           311 to 568    1.10       0.75 to 1.62   0.618                
  Purebred status                                                                                                                                    
   Purebred                               172 (78.5)      532                           424 to 637    Baseline   \-             \-                   0.637
   Crossbred                              47 (21.5)       432                           221 to 726    1.09       0.77 to 1.55   0.635                
  Weight to breed                                                                                                                                    
   Average                                81 (37.0)       479                           332 to 681    Baseline   \-             \-                   0.900
   Above                                  73 (33.3)       596                           441 to 717    0.93       0.65 to 1.33   0.705                
   Below                                  20 (9.1)        373                           199 to 739    1.09       0.61 to 1.95   0.769                
   Crossbreed                             45 (20.6)       389                           217 to 726    1.07       0.72 to 1.60   0.728                
  Treated with trilostane                                                                                                                            
   Yes                                    206 (94.1)      521                           416 to 634    Baseline   \-             \-                   0.600
   No                                     13 (5.9)        178                           3 to 1015     1.20       0.61 to 2.36   0.590                
  Trilostane dose frequency                                                                                                                          
   Once daily                             178 (81.3)      532                           424 to 634    Baseline   \-             \-                   0.372
   Twice daily                            16 (7.3)        833                           311 to 1109   0.71       0.41 to 1.23   0.226                
   Not given                              13 (5.9)        178                           3 to 1015     1.20       0.61 to 2.36   0.584                
   Unknown                                12 (5.5)                                                                                                   
  Mean lifetime trilostane dose (mg/kg)                                                                                                              
   Not given                              13 (5.9)        178                           3 to 1015                                                    
   ≤3                                     68 (31.1)       449                           308 to 605    1.16       0.78 to 1.74   0.462                0.463
   \>3                                    131 (59.8)      596                           427 to 718    Baseline   \-             \-                   
   Missing                                7 (3.2)                                                                                                    
  Comorbidities                                                                                                                                      
  Neurological signs                                                                                                                                 
   Yes                                    45 (20.6)       479                           300 to 596    1.44       1.01 to 2.03   0.042                0.048
   No                                     174 (79.5)      535                           389 to 689    Baseline   \-             \-                   
  Hypertensive                                                                                                                                       
   Yes                                    27 (12.3)       660                           429 to 779    Baseline   \-             \-                   0.881
   No                                     15 (6.9)        479                           178 to 753    0.93       0.46 to 1.84   0.826                
   Not checked                            177 (80.8)      479                           357 to 605    0.87       0.48 to 1.58   0.650                
  Diabetes mellitus                                                                                                                                  
   Yes                                    22 (10.1)       479                           119 to 1102   0.91       0.57 to 1.46   0.698                0.695
   No                                     197 (89.9)      510                           412 to 605    Baseline   \-             \-                   
  No. of comorbidities                                                                                                                               
   0                                      78 (35.6)       334                           225 to 432    Baseline   \-             \-                   
   ≥1                                     141 (64.4)      568                           479 to 715    1.23       0.89 to 1.70   0.198                0.210
  Changes to trilostane                                                                                                                              
   Increased                              55 (25.1)       733                           532 to 941    0.50       0.34 to 0.73   \<0.001              0.002
   Decreased                              23 (10.5)       681                           308 to 830    0.56       0.34 to 0.93   0.023                
   No change                              94 (42.9)       332                           221 to 432    Baseline   \-             \-                   
   Stopped                                34 (15.6)       546                           412 to 717    0.73       0.48 to 1.10   0.133                
   Not given                              13 (5.9)                                                                                                   
  Pre-ACTH cortisol (nmol/l)                                                                                                                         
   Unknown                                154 (70.3)      449                           355 to 605    1.44       0.95 to 2.19   0.089                0.154
   \<150                                  34 (15.5)       577                           340 to 942    Baseline   \-             \-                   
   ≥150                                   31 (14.2)       521                           84 to 831     1.58       0.93 to 2.70   0.092                
  Post-ACTH cortisol (nmol/l)                                                                                                                        
   Unknown                                142 (64.8)      449                           334 to 618    1.48       0.98 to 2.23   0.062                0.091
   \<800                                  36 (16.5)       779                           577 to 1041   Baseline   \-             \-                   
   ≥800                                   41 (18.7)       432                           269 to 535    1.64       1.00 to 2.68   0.049                

\*Wald P value.

†LRT P value.

ACTH, adrenocorticotropic hormone; LRT, likelihood ratio test.

The final multivariable Cox proportional hazards model included three risk factors as well as the clinic ID, included as a frailty term ([table 2](#T2){ref-type="table"}). Dogs greater than or equal to 15 kg had 1.51 the hazard of dying from all-cause mortality compared with those less than 15 kg (95% CI 1.06 to 2.15, P=0.023). Cases greater than or equal to 13 years of age had 3.74 the hazards of death compared with those less than 10 years (95% CI 2.29 to 6.09, P\<0.001). Age was not included as a linear term as this did not improve model fit. Cases that had their starting dose increased had 0.49 the hazards of all-cause mortality compared with those where no dose change was made (95% CI 0.32 to 0.76, P=0.015). No confounding risk factors or interactions were found. Visual interpretation of Cox-Snell residuals showed good model fit and there was no evidence of violation of the proportional hazards assumption.

###### 

Multivariable Cox proportional hazards regression results for risk factors associated with death (all-cause mortality) among dogs diagnosed with hyperadrenocorticism at primary care veterinary practices in England (n=206)

  Variable                   HR         95% CI         Variable P value\*
  -------------------------- ---------- -------------- --------------------
  Bodyweight (kg)                                      
   \<15                      Baseline   \-             0.023
   ≥15                       1.51       1.06 to 2.15   
  Age at diagnosis (years)                             
   \<10                      Baseline   \-             \<0.001
   10 to \<13                1.70       1.14 to 2.54   
   ≥13                       3.74       2.29 to 6.09   
  Changes to trilostane                                
   No change                 Baseline   \-             0.015
   Increased                 0.49       0.32 to 0.76   
   Decreased                 0.78       0.44 to 1.38   
   Stopped                   0.72       0.44 to 1.16   
  Clinic ID                                            LRT of theta=0.023

\*LRT P value.

LRT, likelihood ratio test.

Discussion {#s4}
==========

This study identified a median survival time for diagnosed cases of hyperadrenocorticism within primary care practice in England as 510 days (95% CI 412 to 618 days). This estimate lies comfortably within previous survival time estimates ranging from 353 to 900 days.[@R4] No statistically significant difference in the median survival times of those with ADH (596 days, 95% CI 166 to 941, n=14) and PDH was found (700 days, 95% CI 305 to 1125, P=0.310, n=30). The final multivariable model identified older age at diagnosis, a greater maximum recorded bodyweight and no alteration to the starting trilostane dose as risk factors for increased hazard of death from all-cause mortality. This concurs with previous studies investigating the survival characteristics of dogs with hyperadrenocorticism.[@R5] The increased hazard with increasing age is unsurprising, with older dogs having a naturally shorter expected onward survival to younger dogs. Dogs weighing greater than or equal to 15 kg had one and a half times the hazard of death from all-cause mortality compared with those less than 15 kg in weight. The variable investigating those with a bodyweight greater than the breed average was not significant in the univariable analysis therefore this could suggest a breed difference in survival rather than dogs that are overweight. This could be due to a shorter life expectancy in larger breed dogs[@R30] or that larger breed dogs are thought to be at increased risk of ADH, which in itself has been associated with poorer survival times.[@R31] The variable looking at changes made to the initial trilostane dose interestingly found that the cases with the initial trilostane dose increased were at reduced risk of dying compared with those with no change made to the initial trilostane dose. The association with this needs to be interpreted cautiously. This effect could be due to reverse causality; cases that live longer may be more likely to have a dose change. It could be that dogs with longer survival may have had more frequent veterinary care with more attention paid to optimise the dosage (either increased, decreased or stopped). Also measurement error of the diagnostic screening tests will have resulted in a number of misclassifications therefore dogs having their trilostane stopped could have been initially incorrectly diagnosed with hyperadrenocorticism. As a higher mean lifetime trilostane dose was not significant in the model, it does not seem that higher doses of trilostane favour survival. The presence of at least one comorbidity did not increase the risk of all-cause mortality in this study. It could have been assumed that the additional burden of a comorbidity may worsen quality of life and add financial pressure therefore influencing euthanasia decisions. The presence of neurological signs was suggestive of increased risk of dying in the univariable results but was not significant after accounting for age in the final model and comorbidity with diabetes mellitus was not associated with reduced survival in this study which contradicts the findings of another study.[@R8] The proportion of hyperadrenocorticism dogs with concurrent diabetes mellitus has previously been reported at about 10 per cent--14 per cent[@R5] which is consistent with this study, finding 10 per cent of hyperadrenocorticism cases concurrently had diabetes mellitus.

In this analysis, only 44 (21.1 per cent) cases were differentiated into their origin of hyperadrenocorticism with the option to differentiate often suggested by the attending veterinary surgeon but rarely taken up by owners, even though this is deemed an important step in the diagnosis process by the American College of Veterinary Internal Medicine(ACVIM) consensus guidelines.[@R32] Those cases differentiated were based on interpretation of ultrasonographic imaging of the adrenals or through interpretation of the LDDST with no other methods of differentiation recorded. With the attending veterinarian not always confident in their differentiation and potential measurement error, there is a possibility of misclassification bias of those where an origin of hyperadrenocorticism is recorded. The reason for low uptake of differentiation could be financial, no plans to treat surgically or it was not strongly recommended by the veterinary surgeon. Due to the low numbers of those tentatively differentiated, it was not possible to precisely compare the survival of the two main forms of hyperadrenocorticism in the current study, resulting in low statistical power and wide CIs around the survival estimates. The underlying aetiologies of the two causes of hyperadrenocorticism and their treatment recommendations are quite different yet the overall clinical signs are similar due to the resulting excessive glucocorticoid. They are often grouped together as one disease however in a study such as this, the measure of effect may well be diluted using this approach of a single disease diagnosis.

Median survival for cases treated with trilostane (n=206) was 521 days (95% CI 416 to 634 days) and did not statistically differ from the 18 cases not treated with trilostane (178 days, 95% CI 3 to 1015 days, P=0.590). Due to the low numbers of those untreated resulting in wide CIs and the retrospective design of this observational study, it is not feasible to draw inferences from the comparison of the two treatment groups. A retrospective study in Japan found a significant difference in survival times in those treated with trilostane and those untreated. Interestingly, due to cultural preferences, euthanasia was rarely conducted in Japan reducing some bias that can easily be introduced into observational veterinary studies.[@R6] A future study could be warranted to further investigate the benefits of trilostane treatment.

VetCompass data used in this study are generalisable to veterinary practices in England, with participating practices located across the country using opt-out owner consent.[@R19] There are limitations to this study. The data analysed were not primarily recorded for research purposes. Cases were included if a diagnosis of hyperadrenocorticism was recorded in the EPR, however no independent confirmation of the diagnosis was possible due to the retrospective nature of the data. Additionally, measurement error from the diagnostic screening tests used could have introduced bias into this study. The recommended gold standard diagnostic screening test is the LDDST, which was recorded in only 32.0 per cent of the dogs included.[@R32] The ACTH stimulation was the predominant diagnostic test used in this study population which, with a low sensitivity (ie, the proportion of all true cases that are detected), increases the potential for missed cases in primary care practice and consequently in this study.[@R31] The poor specificity of the UCCR could contribute to misclassification of cases, however this test was always used for diagnosis in combination with an ACTH stimulation or an LDDST for dogs in this study. Therefore, it does not appear that a diagnosis of hyperadrenocorticism was made solely using a UCCR in any of these cases. The outcome of interest was all-cause mortality with the definitive cause of death rarely recorded therefore it was not possible to attribute whether these deaths were as a result of hyperadrenocorticism. The date of diagnosis recorded in the EPR was used as the starting point for survival estimation, which will differ from the date these cases first developed hyperadrenocorticism. Gaining the definitive diagnosis depends on factors such as the severity of the dog's clinical signs to warrant the initial veterinary consultation or development of concurrent disease associated with hyperadrenocorticism, which raise the clinician's suspicion of the disease.[@R37] These factors will vary among dogs and likely underestimate the median survival estimate. There is potential for selection bias in this study. Over 95 per cent of dogs in the current study were treated with trilostane at some point, which reflects the management of hyperadrenocorticism within primary care veterinary practice. Confirming a diagnosis of hyperadrenocorticism requires uptake of diagnostic tests and an initial financial outlay by an owner. It is likely that most decisions to diagnose and later differentiate were made by the owner and attending veterinary surgeon before investigation. Therefore, there will be dogs seen at participating veterinary practices with hyperadrenocorticism that were left undiagnosed and hence not included in this study.[@R37] Another study is warranted to compare the characteristics of dogs suspected of disease and those with a confirmed diagnosis to better understand the reason for not obtaining a definitive diagnosis. In this analysis, 57 per cent of dogs were insured which is a higher proportion than expected.[@R30] This again corresponds with the above argument that the case definition is more likely to have selected for dogs whose owners wish to and were able to investigate and treat. Finally, an assumption of survival analyses is that the survival pattern of those with complete follow up are the same as those censored; however, in a retrospective study this assumption cannot be assessed. Those lost to follow-up by moving practice or the practice can no longer contact may differ from the treated group.

In summary, this study has highlighted the practicalities of hyperadrenocorticism management within primary care practice in England with disease origin infrequently differentiated and trilostane the predominate treatment for the disease. Survival times following diagnosis were generally fair and are consistent with other studies, with prognosis found to be less favourable in dogs of greater bodyweight, those diagnosed at an older age and those where no changes to the starting trilostane dose were made.
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